Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab

J Am Coll Cardiol. 2022 Dec 13;80(24):2356-2359. doi: 10.1016/j.jacc.2022.09.035. Epub 2022 Oct 31.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • C-Reactive Protein
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / prevention & control
  • Heart Disease Risk Factors
  • Humans
  • Lipoprotein(a)*
  • Risk Factors

Substances

  • Lipoprotein(a)
  • C-Reactive Protein